AZD-0120 is a gene-modified cell therapy commercialized by AstraZeneca, with a leading Phase II program in Relapsed Multiple Myeloma;Refractory Multiple Myeloma. According to Globaldata, it is involved in 15 clinical trials, of which 2 were completed, 9 are ongoing, and 4 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of AZD-0120’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for AZD-0120 is expected to reach an annual total of $15 mn by 2040 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
AZD-0120 Overview
GC0-12 is under development for the treatment of advanced relapsed/refractory multiple myeloma, newly diagnosed multiple myeloma, refractory generalized myasthenia gravis, B-cell non-Hodgkin's lymphoma, primary mediastinal b-cell lymphoma, diffuse large b-cell lymphoma, follicular lymphoma, marginal zone b-cell lymphoma, mantle cell lymphoma and systemic lupus erythematosus. The therapy constitutes of genetically manipulated T cells which express dual chimeric antigen receptor targeting tumor cells expressing B-cell maturation antigen (BCMA) and CD19 chimeric antigen receptors. It is developed based on FasTCAR platform. It is administered through intravenous route.
AstraZeneca Overview
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
The company reported revenues of (US Dollars) US$45,811 million for the fiscal year ended December 2023 (FY2023), an increase of 3.3% over FY2022. In FY2023, the company’s operating margin was 17.9%, compared to an operating margin of 8.5% in FY2022. In FY2023, the company recorded a net margin of 13%, compared to a net margin of 7.4% in FY2022.
The company reported revenues of US$12,938 million for the second quarter ended June 2024, an increase of 2% over the previous quarter.
For a complete picture of AZD-0120’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.